Top pharmaceutical companies halt low-end generic drug varieties and APIs are the key to centralized procurement

Top pharmaceutical companies halt “low-end” generic drug varieties and APIs are the key to centralized procurement
As of now, the results of the second batch of centralized national drug purchases have been implemented in many provinces including Beijing, Shandong, and Guangdong, and the price of some drugs has fallen by more than 90%.Judging from the results of the first two batches of collective mining, in addition to domestic enterprises, some of the original pharmaceutical companies also joined.Competition is intensifying, and companies such as East China Pharmaceutical “stop” some low barrier, low commercial value generic drugs.Some experts said that the “optimization” of varieties and the advantages of APIs will become the key to the success or failure of enterprises in the future centralized procurement.The drug price dropped by 90%, and the second batch of national drug centralized procurement results released by the public in January 2020 showed that the purchase of 32 varieties was successful, and a total of 100 products were selected. The average price reduction of drugs was 53%, the highestThe decrease was 93%.Among them, the hypoglycemic drugs acarbose, glimepiride and other chronic diseases are commonly used to reduce amplitude conduction.According to the statistics of Sauna and Yewang, the results of centralized mining have already landed in Beijing, Shandong, Shanghai, Guangdong, Hebei and other places.With the advancement of centralized mining, citizens have also used more cheap medicines with guaranteed quality.Taking acarbose for type 2 diabetes as an example, the dose of 50mg of the original research drug is about 65 yuan per box before the collection and landing. Each box of 30 tablets is taken three times a day and two tablets each time.13 yuan; the price of the drug replaces 5 after the collection and landing.42 / box, a drop of more than 90%, with an average of 0.18 yuan / piece, the patient’s daily treatment cost is 1.08 yuan.Wang Guang, director of the Department of Endocrinology, Beijing Chaoyang Hospital, accepted a sauna interview. Ye Wang said in an interview that diabetic patients cannot be cured. Patients can control blood sugar, blood pressure, blood lipids and other risk factors through long-term standard medication, thus effectively delaying diabetic heart and cerebrovascularProgress of other complications.In clinical practice, certain diabetic patients often combine multiple chronic diseases, and the economic burden of complications caused by long-term medication treatment is, “The price reduction rate of hypoglycemic drugs is reduced in proportion to the collection of this episode, and the patient’s medication compliance will be improved.”” In addition to acarbose, the antipyretic and analgesic acetaminophen reported 0 in the collection.”Cabbage price” of 03 yuan / piece.Pilot Office, the relevant person in charge of the Joint Procurement Office pointed out that the implementation of the “4 + 7” pilot and the nationwide expansion of the implementation exceeded expectations. From the perspective of the pilot area, the proportion of people using generic drugs and original drugs that have passed the consistency evaluation is% Has been greatly increased to more than 90%, and the level of medication quality has been significantly improved.The focus of pharmaceutical companies is to switch to high-end generic drugs and innovative drugs as entry vouchers for centralized procurement, and unanimous evaluation has become a strategic consideration for enterprises.According to developing countries, from purchasing reference preparations, to conducting clinical research, from small to medium-scale production, to bioequivalence testing, review and inspection, to complete the consistency evaluation of a single variety of generic drugs, companies spend 5 millionYuan, more than 10 million yuan.Once it fails, the company sees no return.It is not uncommon for domestic well-known pharmaceutical companies to hold multiple individual approval numbers. If each variety is to be evaluated consistently, the cost is astronomical.Therefore, several domestic companies have focused on high-end generic and innovative drugs.Wang Shanchun, president of Zhengda Tianqing Pharmaceutical Group, told the sauna and Yewang that the company will continue to promote the consistency evaluation of key varieties of generic drugs, and will also strategically abandon some of the market with small capacity, low cost advantage, and fierce competitionVariety.Qi Lu Pharmaceutical Group Vice President Bao Haizhong also said in an interview with that from the first imitation to the first, from “China New” to “Global New”, Qilu Pharmaceutical will continue to develop.East China Pharmaceutical also stated in its annual report released at the end of April that the company adjusted the existing product structure in a comprehensive manner based on the market competition pattern and project research and development progress, and cleared and eliminated some low barrier, low commercial value generic drug development.Sun Piaoyang, the former chairman of Hengrui Medicine, publicly stated that he only makes innovative drugs and high-end generic drugs with core values.In addition to the selection of varieties, the advantages of the raw material end are equally important.Shi Lichen, the founder of Beijing Dingchen Pharmaceutical Consulting Management Center, said that the status of the company’s research products in terms of raw materials will directly affect the company’s quotation when participating in centralized procurement, and companies that do not take the initiative in raw materials, The situation will inevitably be passive.Editor Yue Qingxiu proofreading Wu Xingfa

About the Author